ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV).

M. Bories,1 S. Varnous,2 C. Lefaucheur,3 P. Rouvier,2 R. Guillemain,1 P. Bruneval,1 J. Duong Van Huyen,4 A. Loupy.4

1European Georges Pompidou Hospital, Paris, France
2La Pitié
Salpêtrière Hospital, Paris, France
3Saint-Louis Hospital, Paris, France
4Necker Hospital, Paris, France.

Meeting: 2016 American Transplant Congress

Abstract number: 246

Keywords: Heart transplant patients, HLA antibodies, Vascular disease

Session Information

Date: Monday, June 13, 2016

Session Name: Concurrent Session: Molecular and Bio-Markers in Hearts and VADs - A New Hope

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:30pm-3:42pm

Location: Room 102

Related Abstracts
  • Determinants of Accelerated CAV in Heart Allografts: Major Independent Impact of Circulating DSA
  • Clinical Consequences of Immune-Mediated Allograft Arteriosclerosis: A Population Based Study

Introduction

The role of circulating DSA in addition to traditional cardiovascular risk factors, in the development of accelerated CAV have not been demonstrated. We investigated the role of circulating DSA in the development of accelerated CAV in a large prospective observational cohort of heart transplant recipients.

Methods

This was an observational prospective cohort study, including 723 heart transplant patients from 2 centers between 2004 and 2011. Participants were screened for traditional cardiovascular risk factors, circulating anti-HLA antibodies, and their properties (specificity, HLA class, strength). All patients underwent prospective heart allograft biopsies and angiogram with assessment of CAV lesions. We assessed the independent determinants of CAV at 3 years after transplantation.

Results

A total of 145 patients (20.1%) had circulating DSA at the day of transplantation. 170 patients (23.5%) experienced acute rejection in the first 3 years post-transplant with 128 cases (17.7%) of grade 2R ACR and 83 cases (11.5%) of antibody-mediated rejection (ISHLT pAMR+). At 3 years post transplant 29.7% of patients had CAV (20.8%, 7.4% and 1.5% with CAV scores of 1, 2 and 3 respectively). After adjusting on traditional risk factors (recipient age, primary heart disease, gender, hypertension, tobacco use, dyslipidemia, diabetes mellitus, BMI), donor factors (age, gender, BMI, cause of death), transplant characteristics (cold ischemia time, center, emergency heart transplantation), immunological parameters (circulating DSA at the day of transplantation and acute rejection post transplant), and CMV disease occurence post-transplant, the independent determinants of CAV at 3 years were: donor age (RR=1.05; 95%CI=1.03-1.08), recipient dyslipidemia (RR=2.1; 95%CI= 1.02-4.29), presence of circulating DSA at the day of transplantation (RR=2.45 95%CI=1.45-4.12). Occurrence of pAMR2 post-transplant was also a strong and independent factor associated with CAV at 3 years post-transplant (RR=3.51, IC95%=1.84-6.69). This group showed decreased patient survival (HR=1.8 p=0.01).

Conclusion

Circulating DSA are major determinants of severe arteriosclerosis, independent of traditional cardiovascular risk factors. Antibody-mediated CAV is associated with reduced patient survival.

CITATION INFORMATION: Bories M, Varnous S, Lefaucheur C, Rouvier P, Guillemain R, Bruneval P, Duong Van Huyen J, Loupy A. Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV). Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Bories M, Varnous S, Lefaucheur C, Rouvier P, Guillemain R, Bruneval P, Huyen JDuongVan, Loupy A. Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV). [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/donor-specific-antibody-is-a-major-independent-predictor-of-accelerated-heart-allograft-vasculopathy-cav/. Accessed March 8, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.